Outpatient Treatment for Advanced Multiple Myeloma
Author Information
Author(s): S Brugnatelli, A Riccardi, G Ucci, O Moral, L Barbarano, N Piva, L Piccinini, C Bergonzi, A De Paoli, M Di Stasi, E Rinaldi, G Trotti, M Petrini, E Ascaril
Primary Institution: Universita and Istituto di Ricovero e Cura a Carattere Scientifico Policlinico S. Matteo
Hypothesis
Can poorly myelosuppressive chemotherapy schedules effectively treat advanced multiple myeloma?
Conclusion
Both chemotherapy regimens resulted in similar clinical benefits for patients with advanced multiple myeloma.
Supporting Evidence
- The overall response rate was 43%, with no significant difference between the two treatment arms.
- Median duration of response was 5.9 months, and median survival was 14.1 months.
- 88% of chemotherapy courses were administered on an outpatient basis.
Takeaway
Doctors tested two types of chemotherapy for patients with a serious blood cancer, and both worked about the same with fewer side effects.
Methodology
A multicentre, randomised study comparing cyclophosphamide and epirubicin in patients with advanced myeloma.
Limitations
The study did not establish the clinical role of interferon and steroids in enhancing treatment effectiveness.
Participant Demographics
Patients were primarily resistant to or relapsed following first- and second-line therapies, with a median age of 61 years.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.01
Want to read the original?
Access the complete publication on the publisher's website